- Focused on Developing and Marketing Innovative Therapies for Human and Animal Health including Medical Devices and Clinical Diagnostics. 

- Pursuing Acquisitions and In-Licensing Opportunities to Expand Intellectual Property Portfolio and Seek Strategic Partnerships. 

- Aim to Transform Oncology by Enabling Personalized Treatment Selection, Improving Patient Outcomes and Driving Innovation in Healthcare.

- Evaluating a Groundbreaking Medical Device with Potential to Significantly Enhance Diagnostic Capabilities.

- Exclusive, World-Wide License in Artificial Intelligence / Machine Learning Generative Drug Technology.

Sybleu, Inc. (OTC PINK: SYBE) is a biotechnology company dedicated to developing and marketing therapies for human and animal health, as well as medical devices and clinical diagnostics. SYBE actively pursues strategic acquisitions and in-licensing opportunities to expand its intellectual property portfolio and seek strategic partnerships to bring these technologies to market. With a focus on innovation, SYBE has begun the process of assembling a talented team of senior executives and advisors in order to drive its mission forward.

Currently, SYBE is evaluating strategic opportunities in veterinary medical therapeutics, clinical diagnostics, and medical devices. Addressing the unmet needs in animal health, SYBE is exploring innovative approaches to treat prevalent diseases in companion animals. SYBE evaluation focuses on an immunologic target with the potential to revolutionize treatments.

SYBE is committed to advancing precision medicine. By exploring opportunities in clinical diagnostics, SYBE aims to transform oncology by enabling personalized treatment selection, improving patient outcomes, and driving innovation in healthcare.

SYBE is also revolutionizing the endoscopy market, evaluating a groundbreaking medical device that has the potential to significantly enhance diagnostic capabilities. This innovative technology promises to reshape medical procedures and improve patient care.

The SYBE mission is to revolutionize healthcare through cutting-edge solutions, delivering tangible benefits to patients, clinicians, and the broader healthcare community.

SYBE Describes Competitive Landscape Around Artificial Intelligence and Machine Learning in Small Molecule Drug Discovery

On July 18th SYBE announced preparing to begin advancing small molecule drug therapies for animal and human health utilizing recently in-licensed AI/ML technology coupled with co-owned small molecule patents.

Utilizing AI/ML (Artificial Intelligence/Machine Learning) to screen for highly optimized small molecules targeting specific receptors is a burgeoning field that promises to greatly accelerate drug discovery and development. A recent article in the journal Nature Medicine (https://doi.org/10.1038/s41591-023-02361-0) describes the current state of the field.

Only six companies are listed as having drugs in clinical trials designed using AI/MI. Very recently one of these companies, Recursion, announced a $50M investment by NVIDIA (https://ir.recursion.com/news-releases/news-release-details/recursion-announces-collaboration-and-50-million-investment). Recursion itself recently spent $87.5M acquiring two AI/ML drug discovery companies (https://ir.recursion.com/news-releases/news-release-details/recursion-enters-agreements-acquire-cyclica-and-valence-bolster).

"We are so pleased that we have an exclusive, world-wide license to this AI/ML generative drug technology," said Dr. Harry Lander, Chief Scientific Officer of SYBE. "We anticipate it will add significant value to the Company both as a scientific and strategic asset."

"The field is extraordinarily dynamic right now and consolidation is occurring – this is typical when a brand new technology with the potential for changing the status quo is introduced," said Joseph Vaini, CEO of SYBE.

For more information on $SYBE visit: https://sybleu.com

DISCLAIMER:

CAP/FrontPageStocks/CorporateAds.com (CA) is a third-party publisher and news dissemination service provider. CAP/FPS/CA is NOT affiliated in any manner with any company mentioned herein. CAP/FPS/CA is a news dissemination solutions provider and is NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. CAP/FPS/CA’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. CAP/FPS/ CA is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. CAP/FPS/CA has been compensated $500 by a third party for dissemination of this article.

Disclaimer/Safe Harbor:

These news releases and postings may contain forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Media Contact
Company Name: Sybleu, Inc
Contact Person: Joseph G. Vaini, Chairman and CEO
Email: Send Email
Phone: 800 807 4631
Address:1034 Throggs Neck Expressway
City: Bronx
State: New York
Country: United States
Website: https://sybleu.com/